[1] |
RIZZETTO M. The adventure of delta[J]. Liver Int, 2016, 36(Suppl 1): 135-140. DOI: 10.1111/liv.13018.
|
[2] |
YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
|
[3] |
MIAO Z, XIE Z, REN L, et al. Hepatitis D: advances and challenges[J]. Chin Med J (Engl), 2022, 135(7): 767-773. DOI: 10.1097/CM9.0000000000002011.
|
[4] |
DAI ZC, QI GM. National sero-epidemiological survey of viral hepatitis (volume Ⅰ)1992-1995[M]. Beijing: Scientific and Technical Documents Publishing House, 1997.
戴志澄, 祁国明. 中国病毒性肝炎血清流行病学调查(上卷)1992-1995[M]. 北京: 科学技术文献出版社, 1997.
|
[5] |
ZHAN MY, LIU SL, YI YJ, et al. Molecular biology and sero-epidemiology of hepatitis D virus in China[J]. Bulletin Med Res, 1996, 25(10): 9-11. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ199908004.htm
詹美云, 刘善虑, 易炎杰, 等. 我国丁型肝炎病毒分子生物学和血清流行病学研究[J]. 医学研究通讯, 1996, 25(10): 9-11. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ199908004.htm
|
[6] |
STOCKDALE AJ, KREUELS B, HENRION MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
|
[7] |
CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
|
[8] |
KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. DOI: 10.1053/j.gastro.2018.09.058.
|
[9] |
FARCI P, NIRO GA. Clinical features of hepatitis D[J]. Semin Liver Dis, 2012, 32(3): 228-236. DOI: 10.1055/s-0032-1323628.
|
[10] |
NIRO GA, FERRO A, CICERCHIA F, et al. Hepatitis delta virus: from infection to new therapeutic strategies[J]. World J Gastroenterol, 2021, 27(24): 3530-3542. DOI: 10.3748/wjg.v27.i24.3530.
|
[11] |
MIAO Z, ZHANG S, OU X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221(10): 1677-1687. DOI: 10.1093/infdis/jiz633.
|
[12] |
LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
|
[13] |
LIU HM, TAN ZX, YANG J, et al. Prevalence and clinical characteristics of hepatitis D in southwest of China[J]. Chin J Exp Clin Virol, 2022, 36(1): 85-91. DOI: 10.3760/cma.j.cn112866-20210611-00096.
刘慧敏, 谭朝霞, 杨京, 等. 中国西南地区丁型肝炎的流行状况与临床特征分析[J]. 中华实验和临床病毒学杂志, 2022, 36(1): 85-91. DOI: 10.3760/cma.j.cn112866-20210611-00096.
|
[14] |
Chinese Society of Infectious Disesses, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
|
[15] |
Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[16] |
PERVEEN S, NASIR MI, SHAHID SM, et al. Phylogenetic analysis of HDV isolates from HBsAg positive patients in Karachi, Pakistan[J]. Virol J, 2012, 9: 162. DOI: 10.1186/1743-422X-9-162.
|
[17] |
LIU YM, BAI HX, MA YH, et al. Evaluation of four anti-HDV IgG detection reagents for hepatitis D virus[J]. Chin J Viral Dis, 2022, 12(3): 170-174. DOI: 10.16505/j.2095-0136.2022.0024.
刘玉梅, 白洪霞, 马亚红, 等. 4种丁型肝炎病毒IgG抗体检测试剂的评价[J]. 中国病毒病杂志, 2022, 12(3): 170-174. DOI: 10.16505/j.2095-0136.2022.0024.
|
[18] |
BOTELHO-SOUZA LF, VASCONCELOS MPA, DOS SANTOS AO, et al. Hepatitis delta: virological and clinical aspects[J]. Virol J, 2017, 14(1): 177. DOI: 10.1186/s12985-017-0845-y.
|
[19] |
SAGNELLI C, PISATURO M, CURATOLO C, et al. Hepatitis B virus/hepatitis D virus epidemiology: changes over time and possible future influence of the SARS-CoV-2 pandemic[J]. World J Gastroenterol, 2021, 27(42): 7271-7284. DOI: 10.3748/wjg.v27.i42.7271.
|
[20] |
RIZZETTO M, HAMID S, NEGRO F. The changing context of hepatitis D[J]. J Hepatol, 2021, 74(5): 1200-1211. DOI: 10.1016/j.jhep.2021.01.014.
|
[21] |
EL BOUZIDI K, ELAMIN W, KRANZER K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London[J]. J Clin Virol, 2015, 66: 33-37. DOI: 10.1016/j.jcv.2015.02.011.
|
[22] |
SAFAIE P, RAZEGHI S, ROUSTER SD, et al. Hepatitis D diagnostics: utilization and testing in the United States[J]. Virus Res, 2018, 250: 114-117. DOI: 10.1016/j.virusres.2018.03.013.
|
[23] |
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
|
[24] |
TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
|
[25] |
SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
|
[26] |
LIU YM, LIU XE, ZHUANG H. Advances in development of new anti-HDV drugs[J]. Chin J Viral Dis, 2021, 11(6): 414-419. DOI: 10.16505/j.2095-0136.2021.0054.
刘玉梅, 刘学恩, 庄辉. 丁型肝炎抗病毒新药研究进展[J]. 中国病毒病杂志, 2021, 11(6): 414-419. DOI: 10.16505/j.2095-0136.2021.0054.
|
[27] |
ROGGENBACH I, CHI X, LEMPP FA, et al. HDV seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection[J]. Viruses, 2021, 13(9): 1799. DOI: 10.3390/v13091799.
|
[28] |
WANG Y. Survey of HDV infection and molecular characterization of HDV, HBV and HIV-1 among chronic hepatitis B patients in China[D]. Beijing: Chinese Center for Disease Control and Prevention, 2018.
王彦. 我国丁型肝炎病毒感染情况调查和病毒分子特性研究[D]. 北京: 中国疾病预防控制中心, 2018.
|
[29] |
JANG TY, WEI YJ, YEH ML, et al. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues[J]. J Formos Med Assoc, 2021, 120(1 Pt 2): 303-310. DOI: 10.1016/j.jfma.2020.10.002.
|
[30] |
GU XH, LI QF, WANG YM. Clinical characteristics of the patients with hepatitis B combining hepatitis D infection[J]. Chin J Hepatol, 2001, 9(1): 34-36. DOI: 10.3760/j.issn:1007-3418.2001.01.011.
顾小红, 李奇芬, 王宇明. 伴HDV感染的乙型肝炎患者的临床特征[J]. 中华肝脏病杂志, 2001, 9(1): 34-36. DOI: 10.3760/j.issn:1007-3418.2001.01.011.
|
[31] |
WU S, ZHANG Y, TANG Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1.
|
[32] |
LIAO B, ZHANG F, LIN S, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China[J]. PLoS One, 2014, 9(12): e115888. DOI: 10.1371/journal.pone.0115888.
|
[33] |
LEE AU, LEE C. Hepatitis D review: challenges for the resource-poor setting[J]. Viruses, 2021, 13(10): 1912. DOI: 10.3390/v13101912.
|
[34] |
FARCI P, ANNA NIRO G. Current and future management of chronic hepatitis D[J]. Gastroenterol Hepatol (N Y), 2018, 14(6): 342-351.
|
[35] |
RIZZETTO M, HAMID S. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal[J]. Liver Int, 2021, 41(1): 16-19. DOI: 10.1111/liv.14729.
|